CHEK2 and ovarian carcinoma: In this single-center comprehensive study of germline PALB2 PGVs and the CHEK2_1100delC PGV in breast/ovarian cancer, we show a 1% detection rate for PALB2 PGVs, 1.4% for CHEK2_1100delC, and ~7% for BRCA1/2 PGVs.